Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 4Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × MLN2238 × Clear all
NCT04047797 2025-04-20

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 10 charts
Lymphoid

Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡